Vistagen Therapeutics, Inc. (NasdaqCM: VTGN)
Health Care · Biotechnology · US
$0.20
-15.29% today · -95.1% 1Y
Vistagen Therapeutics, Inc. (NasdaqCM: VTGN) operates in the Biotechnology industry within the Health Care sector. The company is valued at $8.88M and employs 41 people.
Over the last twelve months the share price has lost 95.1%, trading between 0.20 and 5.14.
Tweenvest scores Vistagen Therapeutics, Inc. across four factors: quality 40/100, value 45/100. Its strongest factor is value.
VTGN price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $8.88M
- Revenue (TTM)
- $2.50M
- P/E
- —
- EPS
- -1.66
- Dividend yield
- —
- Beta (5Y)
- 0.33
- 52-week high
- $5.14
- 52-week low
- $0.20
- Avg volume (3M)
- —
- Shares outstanding
- 44.38M
- Employees
- 41
- Next earnings
- —
About Vistagen Therapeutics, Inc.
VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical entity dedicated to advancing and commercializing innovative medications for anxiety, depression, and various other disorders impacting the central nervous system (CNS). A key component of its CNS pipeline is PH94B, a fast-acting neuroactive nasal spray currently in Phase III trials for the rapid treatment of anxiety in adults experiencing social anxiety disorder. PH94B also shows potential for addressing a broader spectrum of anxiety conditions, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder (PTSD), pre-procedural anxiety, and panic disorders. The company's CNS development initiatives further encompass PH10, another quick-acting neuroactive nasal spray, which is in preparation for Phase 2B clinical assessment as a standalone therapy for major depressive disorder (MDD). Additionally, VistaGen is developing AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is being investigated in conjunction with oral probenecid for its potential application in treating levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. VistaGen has established various collaborations, including a contract research and development agreement with Cato Research Ltd., a licensing agreement with Pherin Pharmaceuticals, Inc., and a license and collaboration agreement with EverInsight Therapeutics Inc. Founded in 1998, VistaGen Therapeutics, Inc. is headquartered in South San Francisco, California.
- ISIN
- US92840H4002
- Founded
- 1998
- Listed since
- Jun 21, 2011
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Hemostemix Inc.TSXV: HEM | $8.97M | CA$0.06 | -20.00% |
| Poxel S.A.ENXTPA: POXEL | $8.95M | €0.15 | +10.45% |
| AdAlta LimitedASX: 1AD | $8.94M | AU$0.00 | +14.29% |
| Biovica International AB (publ)OM: BIOVIC B | $8.90M | Skr0.30 | -0.33% |
| 1nKemia IUCT Group, S.A.BME: IKM | $8.80M | €— | — |
| Nanologica AB (publ)OM: NICA | $8.66M | Skr0.26 | -5.78% |
| Brainstorm Cell Therapeutics Inc.OTCPK: BCLI | $8.60M | $0.78 | -17.94% |
| Chemomab Therapeutics Ltd.NasdaqCM: CMMB | $8.55M | $1.18 | +0.85% |
Figures last refreshed Oct 18, 2026.